Pfizer’s modified messenger RNA influenza vaccine prevented influenza better than an already-available shot, according to newly published results from a clinical trial.
The mRNA, or modRNA, vaccine provided 34.5 percent better protection against laboratory-confirmed influenza associated with influenza-like symptoms when compared to a licensed vaccine, researchers with Pfizer, the Kaiser Permanente Washington Health Research Institute, and other institutions reported on Nov. 19 in the New England Journal of Medicine.
The trial was among healthy adults aged 18 to 64 and ran during late 2022 and early 2023 in the Philippines, South Africa, and the United States.
Of 18,476 participants, 9,191 received Pfizer’s vaccine. The rest received the existing shot….